DTG/3TC is a single tablet regimen used in this study. It combines two medications, dolutegravir and lamivudine, into one pill. This combination is used to maintain control of HIV in people who have already achieved viral suppression, meaning the virus is at very low levels in their body. The study is testing how well this combination works when patients switch from another HIV treatment.

BIC/FTC/TAF is another single tablet regimen that combines three medications: bictegravir, emtricitabine, and tenofovir alafenamide. This combination is used to control HIV by keeping the virus at low levels in the body. In this study, patients who are already taking this combination and have their virus under control are switching to the DTG/3TC regimen to see if they can maintain their viral suppression.

Human Immunodeficiency Virus (HIV) – HIV is a virus that attacks the body’s immune system, specifically the CD4 cells (T cells), which are crucial for fighting infections. Over time, HIV can destroy so many of these cells that the body can’t fight off infections and disease. The virus is transmitted through contact with certain body fluids of an infected person, most commonly during unprotected sex or through sharing needles. As the virus progresses, it can lead to acquired immunodeficiency syndrome (AIDS), the most severe phase of HIV infection. During this stage, the immune system is badly damaged, and the body becomes vulnerable to opportunistic infections and certain cancers. Without treatment, HIV can gradually weaken the immune system, but with proper management, individuals can maintain a healthy life.